Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 2, 2015, Pages 69.e11-69.e18

  Lebdai, Souhil ^a   Verhoest, Gregory ^b   Parikh, Hemang ^c   Jacquet, Solène Florence ^b   Bensalah, Karim ^b   Chautard, Denis ^a   Rioux Leclercq, Nathalie ^b   Azzouzi, Abdel Rahmène ^a   Bigot, Pierre ^a,d  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Mass spectrometry; Prognosis; Proteomics; Renal cancer; SSIGN score; Transforming growth factor beta induced protein ig h3

Indexed keywords

ALPHA 1 ACID GLYCOPROTEIN 2; ALPHA 1 ANTITRYPSIN; BINDING PROTEIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C9; EMILIN 1; GALECTIN 3; IMMUNOGLOBULIN KAPPA CHAIN; LACTADHERIN; LAMININ; LAMININ ALPHA5; LUMICAN; NICOTINAMIDE METHYLTRANSFERASE; OROSOMUCOID; PROTEIN; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INDUCED; UNCLASSIFIED DRUG; VITRONECTIN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ANTIGEN RETRIEVAL; ARTICLE; CANCER GENETICS; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DOWN REGULATION; EXTRACELLULAR MATRIX; FOLLOW UP; GENETIC ASSOCIATION; GLYCOGEN ANALYSIS; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METABOLISM; TUMOR NECROSIS; UPREGULATION; WESTERN BLOTTING; FEMALE; GENETICS; KIDNEY TUMOR; MALE; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROGNOSIS; PROTEOMICS;

BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MASS SPECTROMETRY; PROGNOSIS; PROTEOMICS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84923574577     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.06.005     Document Type: Article

References (26)

1. Rini B.I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007, 13:1098-1106.
2. Bensalah K., Montorsi F., Shariat S.F. Challenges of cancer biomarker profiling. Eur Urol 2007, 52:1601-1609.
3. Ljungberg B., Cowan N.C., Hanbury D.C., Hora M., Kuczyk M.A., Merseburger A.S., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
4. Zigeuner R., Hutterer G., Chromecki T., Imamovic A., Kampel-Kettner K., Rehak P., et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 2010, 57:102-109.
5. Comuzzi B., Sadar M.D. Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cellscience 2006, 3:61-81.
6. Gan C.S., Chong P.K., Pham T.K., Wright P.C. Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J Proteome Res 2007, 6:821-827.
7. Masui O., White N.M., DeSouza L.V., Krakovska O., Matta A., Metias S., et al. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics 2010, 12:132-144.
8. Siu K.W., DeSouza L.V., Scorilas A., Romaschin A.D., Honey R.J., Stewart R., et al. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res 2009, 8:3797-3807.
9. Haffey W.D., Mikhaylova O., Meller J., Yi Y., Greis K.D., Czyzyk-Krzeska M.F. iTRAQ proteomic identification of pVHL-dependent and -independent targets of Egln1 prolyl hydroxylase knockdown in renal carcinoma cells. Adv Enzyme Regul 2009, 49:121-132.
10. Chautard D., Dalifard I., Chassevent A., Guyetant S., Daver A., Vielle B., et al. Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. Urology 2004, 63:1055-1060.
11. Bigot P., Mouzat K., Lebdai S., Bahut M., Benhabiles N., Tassin G.C., et al. Quantitative proteomic determination of diethylstilbestrol action on prostate cancer. Asian J Androl 2013, 15:413-420.
12. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
13. Skonier J., Neubauer M., Madisen L., Bennett K., Plowman G.D., Purchio A.F. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol 1992, 11:511-522.
14. Kannabiran C., Klintworth G.K. TGFBI gene mutations in corneal dystrophies. Hum Mutat 2006, 27:615-625.
15. Park S.W., Bae J.S., Kim K.S., Park S.H., Lee B.H., Choi J.Y., et al. Beta ig-h3 promotes renal proximal tubular epithelial cell adhesion, migration and proliferation through the interaction with alpha3beta1 integrin. Exp Mol Med 2004, 36:211-219.
16. Arimoto T., Katagiri T., Oda K., Tsunoda T., Yasugi T., Osuga Y., et al. Genome-wide cDNA microarray analysis of gene-expression profiles involved in ovarian endometriosis. Int J Oncol 2003, 22:551-560.
17. Sasaki H., Kobayashi Y., Nakashima Y., Moriyama S., Yukiue H., Kaji M., et al. Beta IGH3, a TGF-beta inducible gene, is overexpressed in lung cancer. Jpn J Clin Oncol 2002, 32:85-89.
18. Schneider D., Kleeff J., Berberat P.O., Zhu Z., Korc M., Friess H., et al. Induction and expression of beta ig-h3 in pancreatic cancer cells. Biochim Biophys Acta 2002, 1588:1-6.
19. Zhang Y., Wen G., Shao G., Wang C., Lin C., Fang H., et al. TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res 2009, 69:37-44.
20. Matsuda D., Khoo S.K., Massie A., Iwamura M., Chen J., Petillo D., et al. Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Lett 2008, 272:260-267.
21. Calaf G.M., Echiburu-Chau C., Zhao Y.L., Hei T.K. BigH3 protein expression as a marker for breast cancer. Int J Mol Med 2008, 21:561-568.
22. Ivanov S.V., Ivanova A.V., Salnikow K., Timofeeva O., Subramaniam M., Lerman M.I. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun 2008, 370:536-540.
23. Shang D., Liu Y., Yang P., Chen Y., Tian Y. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Urology 2012, 79:966e1-966e7.
24. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
25. Yamanaka M., Kimura F., Kagata Y., Kondoh N., Asano T., Yamamoto M., et al. BIGH3 is overexpressed in clear cell renal cell carcinoma. Oncol Rep 2008, 19:865-874.
26. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 2005, 41:1690-1696.